A Randomized, Open, Single-dose, 2x2x4 Replicate Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of UIC201806 and UIC201602 or Administration of UI018 in Healthy Volunteers
Latest Information Update: 06 Dec 2023
Price :
$35 *
At a glance
- Drugs UI 018 (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Korea United Pharm Inc
- 20 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 25 Oct 2021 New trial record